Eli Lilly and Co. (NYSE: LLY) shares are trading at $813.53 on Thursday morning, inching down 0.01% after a strong run earlier this year. The stock's performance reflects a balance between surging demand for its diabetes and obesity drugs and growing concerns over pricing pressures and supply constraints.
The pharmaceutical company has posted a series of robust quarterly results. In the second quarter of 2025, Eli Lilly reported $15.56 billion in revenue, up 38% from a year earlier, while earnings per share nearly doubled to $6.29. Sales growth was driven primarily by soaring demand for its GLP-1-based therapies, Mounjaro and Zepbound, which continue to dominate the diabetes and obesity treatment markets. On the back of these results, the company raised its full-year revenue forecast to a range of $60 billion to $62 billion and now expects non-GAAP earnings per share of $21.75 to $23.00.
